Gonzalez-Estrada Alexei, Avila-Castano Karol, Irizarry-Alvarado Joan M, Pai Sher-Lu, Volcheck Gerald W
Division of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Fla.
Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Fla.
J Allergy Clin Immunol Glob. 2022 Oct 30;2(1):88-92. doi: 10.1016/j.jacig.2022.09.010. eCollection 2023 Feb.
A previous study, using administrative data, reported an incidence of perioperative anaphylaxis (POA) of 1:6537 procedures in the United States.
We sought to determine the incidence of POA in a prospective US cohort.
Adult participants undergoing a procedure at a single tertiary care center were studied prospectively between April 2018 and January 2022. Subinvestigators recorded vital signs and skin checks preoperatively, 15 minutes into induction, and hourly thereafter until 1 hour into the postoperative period. If participants developed an adverse reaction, additional variables were documented: causal agent(s) exposure, type of nonallergic adverse reaction, Sixth National Audit Project severity score, evidence of mast cell activation by serum acute and baseline tryptase pairing, Allergy consult, and causal agent identification.
Among 939 procedures (mean age, 59.25 ± 14.78 years; 58% females; 87% White), there were 12 (1.3%) cases with an identified adverse reaction. Nine cases were classified as nonhypersensitivity adverse reactions (1%) and 3 as possible hypersensitivity reactions (0.3%); 1 case was classified as suspected perioperative hypersensitivity and 2 as POA (0.2%). Both POA cases were males, had previous procedures, had evidence of mast cell activation, had a Sixth National Audit Project score of 3, and were referred to Allergy for further evaluation. There were 9 participants who developed a nonhypersensitivity adverse reaction: relative overdose of anesthetic (n = 6), transient rash (n = 2), and isolated bronchospasm (n = 1). All transient rashes were observed during undraping protocol.
In our prospective study, the incidence of POA is 1:470 procedures. Our study suggests that the incidence of POA may be higher than previously reported.
一项先前使用行政数据的研究报告称,在美国,围手术期过敏反应(POA)的发生率为每6537例手术中有1例。
我们试图确定美国一个前瞻性队列中POA的发生率。
对2018年4月至2022年1月期间在一家单一的三级医疗中心接受手术的成年参与者进行前瞻性研究。子研究人员在术前、诱导开始后15分钟以及此后每小时记录生命体征和皮肤检查情况,直至术后1小时。如果参与者出现不良反应,则记录其他变量:接触的致病因素、非过敏性不良反应的类型、第六次国家审计项目严重程度评分、血清急性和基线类胰蛋白酶配对显示的肥大细胞活化证据、过敏咨询以及致病因素鉴定。
在939例手术中(平均年龄59.25±14.78岁;58%为女性;87%为白人),有12例(1.3%)出现了已确定的不良反应。9例被归类为非超敏反应性不良反应(1%),3例为可能的超敏反应(0.3%);1例被归类为疑似围手术期超敏反应,2例为POA(0.2%)。两例POA病例均为男性,曾接受过手术,有肥大细胞活化的证据,第六次国家审计项目评分为3分,并被转诊至过敏科进行进一步评估。有9名参与者出现了非超敏反应性不良反应:麻醉剂相对过量(n = 6)、短暂性皮疹(n = 2)和孤立性支气管痉挛(n = 1)。所有短暂性皮疹均在解开手术单操作过程中观察到。
在我们的前瞻性研究中,POA的发生率为每470例手术中有1例。我们的研究表明,POA的发生率可能高于先前报道的水平。